1. Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.
- Author
-
Selivanova SV, Stellfeld T, Heinrich TK, Müller A, Krämer SD, Schubiger PA, Schibli R, Ametamey SM, Vos B, Meding J, Bauser M, Hütter J, and Dinkelborg LM
- Subjects
- Animals, Chemistry Techniques, Synthetic, Fluorine Radioisotopes, Humans, Matrix Metalloproteinase Inhibitors chemistry, Matrix Metalloproteinase Inhibitors pharmacology, Mice, Mice, Inbred C57BL, Drug Design, Matrix Metalloproteinase 2 metabolism, Matrix Metalloproteinase 9 metabolism, Matrix Metalloproteinase Inhibitors chemical synthesis, Multimodal Imaging methods, Positron-Emission Tomography, Tomography, X-Ray Computed
- Abstract
The activity of matrix metalloproteinases (MMPs) is elevated locally under many pathological conditions. Gelatinases MMP2 and MMP9 are of particular interest because of their implication in angiogenesis, cancer cell proliferation and metastasis, and atherosclerotic plaque rupture. The aim of this study was to identify and develop a selective gelatinase inhibitor for imaging active MMP2/MMP9 in vivo. We synthesized a series of N-sulfonylamino acid derivatives with low to high nanomolar inhibitory potencies. (R)-2-(4-(4-Fluorobenzamido)phenylsulfonamido)-3-(1H-indol-3-yl)propanoic acid (7) exhibited the best in vitro binding properties: MMP2 IC50 = 1.8 nM, MMP9 IC50 = 7.2 nM. Radiolabeling of 7 with no carrier added (18)F-radioisotope was accomplished starting from iodonium salts as precursors. The radiochemical yield strongly depended on the iodonium counteranion (ClO4(-) > Br(-) > TFA(-) > tosylate). (18)F-7 was obtained in up to 20% radiochemical yield (decay corrected), high radiochemical purity, and >90 GBq/μmol specific radioactivity. The radiolabeled compound showed excellent stability in vitro and in mice in vivo.
- Published
- 2013
- Full Text
- View/download PDF